Dr. John Cush RheumNow
1 year 9 months ago
Early RA Journey - Patient Perspectives and Uncertainties
Canadian early RA (ERA) patients were interviewd to depict their perspectives from onset and diagnosis to referral and care. This report highlights the importance of patient pain and primary care physician (PCP) intake… https://t.co/gwNL7iZIT5 https://t.co/SL0Jw0H8f6
Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology. It is considered among the febrile autoinflammatory etiologies. Now a cohort study shows that AOSD patients may be enriched in germline variants usually limited to monogenic autoinflammatory disorders.
Dr. John Cush RheumNow
1 year 9 months ago
T cell study of bronchoalveolar lavage fluid, blood & synovium from 17 early RA ACPA+ pts (TCR sequencing & immunophenotyping) found shared lung/joint T cell repertoires driven by smoking. The RA TCR repertoire shaped by MHC predisposition, smoking leading to autoimmunity… https://t.co/0lEVwEbKcW https://t.co/YrhV79AvX4
Dr. John Cush RheumNow
1 year 9 months ago
Late-onset axSpA (LOS) is more likely to have peripheral arthritis. but less HLA-B27 & +FHx of AS/SpA. Portugese study of 2165 axSpA pts. 273 LOS (Sx onset >45 yrs; mean 51yrs; 55% men) had less B27 (51% vs 65%), +FHx (8% vs 14%), inflam LBP (81% vs 88%), Uveitis (13% vs 20%)… https://t.co/DgRUt1ejxT https://t.co/dGX2bfKhnK
Dr. John Cush RheumNow
1 year 9 months ago
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/vwNFU501di
The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and treatment options for children and adults with this condition.
Dr. John Cush RheumNow
1 year 9 months ago
Gut microbiome changes linked to onset of RA
Changes in the make-up of the gut microbiome are linked to the onset of clinically evident rheumatoid arthritis in those at risk of the disease because of genetic, environmental, or immunological factors, suggests research published… https://t.co/gUgYLOKrI0 https://t.co/d75NmKup2U
Dr. John Cush RheumNow
1 year 9 months ago
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/OIornA9sAA https://t.co/yXyX5k2yqD
Dr. John Cush RheumNow
1 year 9 months ago
AMA report says..... " More than one in three physicians, 34 percent, have had a medical liability lawsuit filed against them at some point in their careers"
- Nearly half of physicians >55 have been sued (vs 6% in MDs <40yrs)
- Female physicians are less likely to be sued than… https://t.co/hIUH7Tx85L https://t.co/V2sHyac3XH
Dr. John Cush RheumNow
1 year 9 months ago
Scleroderma registry enrolled SSc pts w/o ILD. Incident ILD occurred in 199/969 (21%) pts over median 2.4yrs. Late onset SSc-ILD (>7yr from Raynauds) occurs 32% less. These pts were more White, w/ arthritis & RNA-polymerase III Abs, but have similar ILD Progression (vs… https://t.co/zdL4OPEPhi https://t.co/wl9XmsCHIE
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.
A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower risks of incident gout and recurrent gout flares among overweight or obese people.
Dr. John Cush RheumNow
1 year 9 months ago
Systematic review suggests (although not provn) that audiovestibular dysfunction may be from APS. Anti-phospholipid & HSP-70 Abs found 25-33% w/idiopathic sudden sensorineural hearing loss,. ACL Abs seen in up to 27% w/ sensorineural hearing loss https://t.co/GTcLoM0SCZ https://t.co/afFntYnPPG
Dr. John Cush RheumNow
1 year 9 months ago
FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/Nq09iEoxJ9 https://t.co/JG4P8zMw9j
